Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph H Butterfield

Showing results (61-70 of 92) with videos related to

Pageof 10
Sort By:
Immunopharmacology and Immunotoxicology|January 25, 2012
Serotonin and its 5-HT1 receptor in human mastocytosisMarkus Ritter, Husameldin El-Nour, Mari-Anne Hedblad, et al.
Haematologica|July 7, 2018
Preclinical human models and emerging therapeutics for advanced systemic mastocytosisMichel Arock, Ghaith Wedeh, Gregor Hoermann, et al.
The Journal of Allergy and Clinical Immunology|December 12, 2018
Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & ImmunologyMelody C Carter, Dean D Metcalfe, Almudena Matito, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 26, 2014
Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reactionRegan C Pyle, Joseph H Butterfield, Gerald W Volcheck, et al.
Molecular Cancer Therapeutics|August 12, 2016
BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid LeukemiaLi-Tzong Chen, Chiung-Tong Chen, Weir-Torn Jiaang, et al.
International Archives of Allergy and Immunology|July 1, 2019
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation SyndromePeter Valent, Patrizia Bonadonna, Karin Hartmann, et al.
The American Journal of Hospice & Palliative Care|May 5, 2018
Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With CancerDavid J Bartlett, Daniel S Childs, Carmen Radecki Breitkopf, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 6, 2025
Sex differences in urinary mast cell mediators: Implications for diagnosing atopic and mast cell disordersValerie Jaroenpuntaruk, Sarah M Jenkins, Carin Y Smith, et al.
American Journal of Hematology|July 3, 2025
Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic SystemFnu Aperna, Maymona G Abdelmagid, Mahesh Kumar, et al.
The Journal of Allergy and Clinical Immunology|September 3, 2019
AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and managementCatherine R Weiler, K Frank Austen, Cem Akin, et al.
Pageof 10

Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
Immunopharmacology and Immunotoxicology|January 25, 2012
Serotonin and its 5-HT1 receptor in human mastocytosisMarkus Ritter, Husameldin El-Nour, Mari-Anne Hedblad, et al.
Haematologica|July 7, 2018
Preclinical human models and emerging therapeutics for advanced systemic mastocytosisMichel Arock, Ghaith Wedeh, Gregor Hoermann, et al.
The Journal of Allergy and Clinical Immunology|December 12, 2018
Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & ImmunologyMelody C Carter, Dean D Metcalfe, Almudena Matito, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 26, 2014
Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reactionRegan C Pyle, Joseph H Butterfield, Gerald W Volcheck, et al.
Molecular Cancer Therapeutics|August 12, 2016
BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid LeukemiaLi-Tzong Chen, Chiung-Tong Chen, Weir-Torn Jiaang, et al.
International Archives of Allergy and Immunology|July 1, 2019
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation SyndromePeter Valent, Patrizia Bonadonna, Karin Hartmann, et al.
The American Journal of Hospice & Palliative Care|May 5, 2018
Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With CancerDavid J Bartlett, Daniel S Childs, Carmen Radecki Breitkopf, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 6, 2025
Sex differences in urinary mast cell mediators: Implications for diagnosing atopic and mast cell disordersValerie Jaroenpuntaruk, Sarah M Jenkins, Carin Y Smith, et al.
American Journal of Hematology|July 3, 2025
Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic SystemFnu Aperna, Maymona G Abdelmagid, Mahesh Kumar, et al.
The Journal of Allergy and Clinical Immunology|September 3, 2019
AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and managementCatherine R Weiler, K Frank Austen, Cem Akin, et al.
Pageof 10